EDMONTON, Alberta--(BUSINESS WIRE)--Canada’s top business magazine, Canadian Business and Maclean’s magazine today jointly released the 30th Annual ranking of Canada’s 500 Fastest-Growing Companies placing BioNeutra (TSXV:BGA) at No.1 in Edmonton and No. 55 overall in Canada.
The magazines slotted BioNeutra in the top 60 companies in Canada on its 2018 Growth 500 rankings based on the Company’s five-year revenue growth of 1,378%. The ranking is the country’s most definitive list of the fastest growing businesses in Canada.
BioNeutra North America Inc will be profiled with other winners in a special print issue of Canadian Business (packaged with the October issue of Maclean’s magazine) and online at canadianbusiness.com and growth500.ca.
BioNeutra is a growth leader among companies in Western Canada – toping the $20-$50 million revenue category in the west. Last year BioNeutra posted sales of more than $1/2 million a week and ended the year with revenue of $32.1 million. This year, revenue jumped again with sales for the first six months running at nearly $900,000 a week.
‘Growth 500’ organizers describe the companies that make its prestigious list as “entrepreneurial superstars” who are some of the most “innovative businesses” in the country.
“The companies on the 2018 Growth 500 are truly remarkable. Demonstrating foresight, innovation and smart management, their stories serve as a primer for how to build a successful entrepreneurial business today,” says Deborah Aarts, Growth 500 editor and program manager. “As we celebrate 30 years of the Canada’s Fastest-Growing Companies programs, it’s encouraging to see that entrepreneurship is healthier than ever in this country.”
“BioNeutra is honored to be recognized by the country’s most highly regarded business ranking,” says Dr. Jianhua Zhu, BioNeutra president, CEO and founder and adds, “but to be among the top 60 companies nationwide in our first ranking is a tribute to our outstanding team of dedicated, hard-working employees who continue to turn in a remarkable performance. We’re grateful to them and our world-wide customers who have contributed to our success.”
Board Chair and former Edmonton Mayor Bill Smith says, “BioNeutra’s sales growth is off the charts. We’re thrilled by the Company’s performance and recognition as one of Canada’s most successful growth companies.”
BioNeutra is a business and science awards leader. Earlier this year it was chosen for the third consecutive year by the Globe and Mail’s Report on Business magazine for its list of Canada’s top 1000 publicly traded companies ranked by revenue.
View the complete rankings of Canada's Fastest-Growing Companies at growth500.ca.
About the Growth-500
For 30 years, the Growth-500 has been Canada's most respected and influential ranking of entrepreneurial achievement. Ranking Canada’s Fastest-Growing Companies by five-year revenue growth, the Growth 500 - formerly known as the PROFIT 500 - profiles the country’s most successful growing businesses. The Growth 500 is produced by Canadian Business. Winners are profiled in a special Growth 500 print issue of Canadian Business (packaged with the October issue of Maclean’s magazine) and online at growth500.ca and CanadianBusiness.com. For more information on the ranking, visit growth500.ca.
About Canadian Business
Founded in 1928, Canadian Business is the longest-serving and most-trusted business publication in the country. It is the country's premier media brand for executives and senior business leaders. It fuels the success of Canada's business elite with a focus on the things that matter most: leadership, innovation, business strategy and management tactics. Learn more at CanadianBusiness.com.
BioNeutra is a multiple-award winning, sector-leading, science-based company committed to improving public health. The media describes it as “…a rising star.” Its lead product is VitaFiber - a healthy low-calorie sweetener which is a dietary fiber and is designed to help with two of the world’s growing health problems - weight management and digestive health. VitaFiber, is the result of a patented process developed over 27 years and is approved for sale in 30 countries after the world’s top three health regulators reviewed the body of science including a human trial submitted during the review process.